Earnings ·
Dr. Reddy's reports Q2 revenue of ₹86.7B and profit after tax of ₹9.3B
RDYDR Reddys Laboratories Ltd
Dr. Reddy’s Laboratories reported consolidated revenues of ₹86,708 million for the quarter ended September 30, 2026, a decline of 1.5% year-over-year but an increase of 7.4% sequentially. Profit after tax attributable to equity holders stood at ₹9,250 million (EPS: ₹11.10), down 36% from the prior year period but up 109% from the previous quarter, which was impacted by a ₹2,397 million provision for semaglutide API issues. EBITDA reached ₹17,828 million with a margin of 20.6%. For the half-year, revenues were ₹167,413 million and profit after tax was ₹13,685 million. The company operates in the global pharmaceutical industry, manufacturing generic drugs, biosimilars, active pharmaceutical ingredients, and contract development and manufacturing services.